The issue of pregnancy and antiviral therapy for chronic hepatitis B (CHB) is a very difficult and challenging issue that we clinicians must face on a daily basis. At present, many domestic and international guidelines for the prevention and treatment of CHB have not addressed this issue in depth and in detail, which is a blind spot and a forbidden area in current medicine. The use of oral anti-hepatitis B virus drugs during pregnancy requires the guidance of a medical professional and a full discussion with the patient and her family to weigh the pros and cons. 1. Indications for antiviral therapy: All cirrhotic patients, those with HBV DNA >107copies/ml in the third trimester, and those with a history of HBV(+) infant delivery and HBV DNA >106copies/ml need antiviral therapy. Recently, some experts also suggest that as long as there is a history of HBV(+) infant delivery, regardless of their HBV DNA level, they need antiviral treatment; for patients with hepatitis activity or suspected cirrhosis, antiviral treatment is needed even in early pregnancy. For patients with cirrhosis, antiviral therapy should be started before pregnancy and continued throughout pregnancy and for a long time after delivery. For non-cirrhotic patients, antiviral treatment should be started at 32 or 34 weeks of gestation and continued until delivery, or until 4 weeks after delivery, depending on the condition. Recently Bzowej NH recommended that antiviral therapy be started at the end of the second trimester, i.e. 26-28 weeks of gestation, for those with a history of HBV(+) infant delivery, or HBVDNA >107copies/ml. 3. Drug selection: Because of the proliferation-inhibiting effects of common interferon and PEG-interferon, such drugs are prohibited for use during pregnancy. According to the available evidence-based medical safety evidence, one of the three nucleoside analogues, lamivudine, tenofovir (currently not available in China) and telbivudine, is recommended.